Navigation Links
Synergy Life Science Partners Closes $143M Debut Medical Device Fund
Date:1/9/2008

PORTOLA VALLEY, Calif., Jan. 9 /PRNewswire/ -- Synergy Life Science Partners, LP, a venture capital limited partnership focused on investments in emerging medical device technologies, today announced the successful completion of fundraising for its debut fund with an aggregate of $143 million in committed capital. The firm has closed on six investments to date.

Founded in 2006 by John Onopchenko, Richard Stack, M.D., and William Starling, Synergy invests directly in private, early-stage medical device firms or emerging companies that are developing disruptive technologies to address unmet or under-served human healthcare needs. Areas of therapeutic interest include cardiovascular disease, orthopedic and spinal diseases and injuries, metabolic disorders such as diabetes and obesity, neuro-mediated disorders, oncology and ophthalmic conditions.

"We're excited about our fundraising accomplishments and our early portfolio," said Onopchenko, a managing director of Synergy. "We've received a great deal of support from our new limited partners, who share our vision for building and accelerating the delivery of innovative medical products. Our goal is to help dramatically improve the standard of patient care in our therapeutic categories, while generating exceptional returns to the customers of and investors in our portfolio companies."

For Synergy's limited partners, the decision to participate has been based on a unique set of factors. "Synergy's innovative strategy for medical device investing is an ideal fit for our portfolio," said Tracy Harris, Director for Parish Capital Advisors, LLP. "We believe the unmatched industry expertise of the managing directors and the fund's strategy of targeting early-stage companies in large therapeutic areas position Synergy to offer outsized returns for investors."

Synergy intends to invest in early-stage companies in large therapeutic areas in both the medical device and the combination product sector. Synergy seeks companies with productive, domain-experienced leadership teams. Additionally, Synergy has the right to invest in companies initiated by Synecor, LLC, a medical device incubator co-founded by Stack and Starling.

Over the last 25 years, Synergy's three principals have established themselves as successful, highly respected venture capital investors, inventors, entrepreneurs, and senior leaders in the healthcare industry.

Onopchenko has spent his entire 25-year career in the medical device field, including senior management positions at General Electric and Johnson & Johnson. Most recently, he was the lead medical device investor for Johnson & Johnson Development Corporation, one of the largest corporate venture investors in the healthcare industry. Companies he has invested in and served as a director of include Volcano, Epicor, NuVasive, Vascular Control Systems, and Vivant Medical.

In addition to co-founding Synecor, Stack is a prolific educator, researcher, and inventor with 28 years experience as an international medical device thought leader. Formerly the head of interventional cardiology at Duke University Medical Center, he has authored 360 manuscripts, book chapters, and abstracts, been a principal or co-principal investigator for three National Institutes of Health grants, and received multiple research awards, including the International Award for Best Experimental Researcher in 1995 from Thoraxcenter, the Netherlands. He currently holds 70 worldwide patents and patents pending for a variety of vascular and therapeutic devices, many of which have been adopted worldwide.

Starling, also a Synecor co-founder, has spent 30 years in the medical device industry. He was a founding management team member for Advanced Cardiovascular Systems, Inc. (acquired by Lilly/Guidant/Abbott), and was a co-founder, officer, and board member of Ventritex, Inc. (IPO in 1992, acquired by St. Jude Medical in 1997). In 1992, he was cofounder, chairman, and president and chief executive officer of Cardiac Pathways Corporation (IPO in 1996, acquired by Boston Scientific Corporation in 2001). Starling has been primarily responsible for raising more than $300 million in private and public capital for the companies that he has co-founded, which have combined annual revenues exceeding $2.75 billion.

About Synergy Life Science Partners

Founded in 2006 by John Onopchenko, Richard Stack, M.D., and William Starling, Synergy Life Science Partners, LP, is a venture capital fund based in Portola Valley, CA that invests directly in private, early-stage medical device firms or emerging companies that are developing breakthrough, disruptive technologies to address unmet or underserved human healthcare needs. For more information, call 650-854-9171 or visit http://www.synergylsp.com.

Information Contact:

Tracy Pappas, Chief Financial Officer

Synergy Life Science Partners

650-854-9171

tpappas@synergylsp.com


'/>"/>
SOURCE Synergy Life Science Partners, LP
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Health Integrated to Showcase Synergy Personal Health Management(R) at DMAA Conference
2. U.S. Research Funding Continues to Flatten as U.S. Health Costs Climb - in August 31 Science
3. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
4. Edwards Lifesciences to Present at the Bear Stearns 20th Annual Healthcare Conference
5. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
6. HealthFitness CEO Supports Move Toward Cultural Shift, and Science-Based Health Management Programming
7. Sangamo BioSciences to Present at the ThinkEquity Partners Growth Conference
8. John B. Buse, MD, PhD of Chapel Hill, NC, Elected American Diabetes Association President, Medicine & Science
9. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
10. SAMHSA Announces First Science and Service Award Winners
11. Novavax CEO to Present at the 2007 UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2016)... , ... April 30, 2016 , ... ... Studios. With inMotion3D Abstract users can distort and manipulate three-dimensional shapes with ease ... rotation, columns, rows, ranks, point, lines, polygons, polygon texture animation, opacity texture animation, ...
(Date:4/30/2016)... ... April 30, 2016 , ... ... News on April 4th, 2016 questioned the use of the HyProCure sinus ... as “a controversial procedure.” EOTTS-HyProCure is a minimally invasive procedure performed, when ...
(Date:4/29/2016)... ... ... In an article published April 16th on the New York ... injections, which she underwent in order to feel more at home at this year’s ... article explains that Ms. Mirmelli’s situation is not unique; many plastic surgeons say they’ve ...
(Date:4/29/2016)... ... ... On Tuesday, April 26, 2016 members of the HomeTown Health network, a network ... on SB 258, the “Rural Health Care Relief” Bill. , The bill, which was ... individuals and corporations which donate directly to a “rural hospital” in Georgia, and goes ...
(Date:4/29/2016)... ... April 29, 2016 , ... Coast Dental Fort Stewart ... at its new location in the Exchange Furniture Mall at 112 Vilseck Road in ... 50-inch Samsung Smart TV. Plus attendees will have the opportunity to meet general dentists ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... 2016 , Net Sales of $1.90 billion ... the prior year period, and an increase of 1.2% on ... EPS for the first quarter were $0.52 reported, a decrease ... an increase of 29.9% over the prior year period ... guidance for 2016 Zimmer Biomet Holdings, Inc. (NYSE ...
(Date:4/28/2016)... , April 28, 2016 Oramed ... a clinical-stage pharmaceutical company focused on the development of oral ... in the upcoming PIONEERS 2016 conference, presented by Joseph ... 2016 in New York . Nadav ... at the conference. Presentation Details:   ...
(Date:4/28/2016)... April 28, 2016  ValGenesis, Inc., the ... Solutions (VLMS) today announced that a prominent ... sufferers of chronic kidney failure has selected ... their corporate validation process. The global medical ... solution to manage their validation processes electronically. ...
Breaking Medicine Technology: